Skip to main content
UniHealth

Doctor search

Nancy L Carteron, MD

Rheumatology · Berkeley

NPI 1669582458

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
9
1 carrier
Offices
2
Since medical school
44 years
Johns Hopkins University School of Medicine, 1982

Offices

2 locations · Regents of the University of California at Berkeley · University of California San Francisco

Looking this up.

Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.

Plans that list them

9 plans · 1 carrier

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Carteron’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026

California Medical Board record

Licence G52227 · Current

Licensed to practise in California · since 1984 · expires 2028-03-31 · Johns Hopkins University School of Medicine. Board flags: Malpractice Judgment.

Public record actions

Actions the Medical Board of California publishes for this licence
1997-06-02Malpractice judgment$239,000 · San francisco county superior court · 970124

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend it
    Overall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at UCSF Medical Center
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths4.9 (3.79 to 6.02) · 7,590 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits12.8 (11.3 to 14.4) · 2,019 casesWorseJan 2024 – Dec 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths139.4 (110.22 to 168.58) · 452 casesBetterJul 2022 – Jun 2024
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.622BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.626BetterOct 2024 – Sep 2025
MRSA BacteremiaInfections0.491BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.8 (0.7 to 1) · 2,336 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.24 (0.58 to 1.9) · 4,689 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths1.05 (0.89 to 1.2)No differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.9 · 89 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths7.5 · 85 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths10.1 · 132 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.6 · 454 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 618 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths9.6 · 380 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.7 · 5,000 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.22 (0.06 to 0.38) · 15,965 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.2 (0.05 to 0.35) · 17,859 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.85 (0 to 1.83) · 4,184 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2 (1.1 to 2.9) · 6,516 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths7.35 (4.49 to 10.21) · 3,989 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5 (3.22 to 6.77) · 4,087 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.95 (0.74 to 3.15) · 2,034 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.95 (0.63 to 1.28) · 15,431 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 399 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.899No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.689No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections1.224No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16 · 156 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20 · 564 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits60.3 · 160 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-9.7 · 550 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits44.1 · 660 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.8 · 667 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.7 (4.8 to 6.7) · 2,019 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits6 · 421 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.5 · 53 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits20 · 107 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits13.9 (11.3 to 17.1) · 3,247 casesNo differentJan 2022 – Dec 2024

What patients said (3,181 patients answered, 25% of those asked)

Patient survey stars by topic at UCSF Medical Center
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at UCSF Medical Center
Room was "always" clean71%
Nurses "always" communicated well80%
Doctors "always" communicated well80%
Staff "always" explained61%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge87%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect86%
Patients who gave a rating of "9" or "10" (high)76%
Staff "always" explained new medications75%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully78%
Nurses "always" treated them with courtesy and respect86%
"Always" quiet at night50%
"YES", patients would definitely recommend the hospital81%
Staff "always" explained possible side effects46%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$4,830

Medicare paid this office $4,830 for 26 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Who their Medicare patients are

26 Original Medicare patients in 2024. Average age 71 · Health risk score 1.99. Sicker patients than 9 in 10 peers; the typical rheumatology clinician is at 1.38.

Conditions among them: High blood pressure 73% · Depression 42%.

The office billed $11,001, Medicare allowed $6,170 and paid $4,830; for 34 services of 7 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
20242634711.99$11,001$4,830
20232021712.23$6,972$2,770
20191215613.35$8,237$825
2017110600671.60$73,270$43,410
2016151786681.52$132,983$65,935
2015155669681.60$165,325$63,857
2014143522671.44$132,444$56,565
2013144591671.59$150,672$69,369

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2019: 1 service

Original Medicare services billed in 2019
Return visit (30+ min)11$726$60

2017: 7 services

Original Medicare services billed in 2017
Long return visit (40+ min)86$19,988$112
Return visit (30+ min)39$5,845$90
Complete ultrasound scan of joint25$4,537$116
Extended patient service without direct patient contact, first hour26$2,599$96
Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month44$2,296$35
Short return visit (20+ min)15$1,850$64
Ultrasound scan of head and neck soft tissue13$1,510$116

2016: 7 services

Original Medicare services billed in 2016
Long return visit (40+ min)121$35,223$124
Return visit (30+ min)49$9,606$92
New patient visit (60+ min)28$5,010$179
Short return visit (20+ min)39$3,929$63
Complete ultrasound scan of joint19$2,816$117
Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month44$2,314$37
Injection, triamcinolone acetonide, not otherwise specified, 10 mg14$60None

2015: 7 services

Original Medicare services billed in 2015
Long return visit (40+ min)106$29,947$123
Return visit (30+ min)68$11,375$95
New patient visit (60+ min)41$7,359$179
Short return visit (20+ min)44$5,484$67
Complete ultrasound scan of joint24$4,542$120
Ultrasound scan of head and neck soft tissue11$1,564$120
Injection, triamcinolone acetonide, not otherwise specified, 10 mg11$94None

2014: 4 services

Original Medicare services billed in 2014
Long return visit (40+ min)104$29,225$132
Return visit (30+ min)78$14,132$97
New patient visit (60+ min)30$5,470$182
Short return visit (20+ min)40$4,269$69

2013: 5 services

Original Medicare services billed in 2013
Long return visit (40+ min)127$44,683$130
Return visit (30+ min)52$7,958$97
New patient visit (60+ min)24$4,516$188
Complete ultrasound scan of joint21$3,544$127
Short return visit (20+ min)33$3,230$67

Drugs they prescribed that Part D paid

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their 22 Part D prescriptions in 2023. Too few prescriptions to judge: with under about 50 a year, a handful of patients can swing this share.

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

Year by year

Part D prescribing by year
202322None0% (0)None$690
202012None0% (0)None$335
201926None0% (0)None$18,188
201815None0% (0)0%$1,131
2017358640% (0)28%$390,009
201657183None35%$667,656
201563996NoneNone$469,285
2014802106None33%$439,867
201392899None30%$419,128

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2017: 7 drugs

Part D drugs prescribed in 2017
Humira12$118,093$9,841
Enbrel17$97,095$5,711
Enbrel Sureclick17$82,908$4,877
Hydroxychloroquine Sulfate54$7,445$138
Methotrexate36$2,868$80
Prednisone40$650$16
Montelukast18$257$14

2016: 14 drugs

Part D drugs prescribed in 2016
Enbrel52$248,332$4,776
Humira19$141,152$7,429
Cosentyx19$121,017$6,369
Hydroxychloroquine Sulfate80$12,870$161
Methotrexate40$3,861$97
Prednisone75$1,505$20
Pilocarpine11$1,063$97
Celecoxib12$1,030$86
Synthroid12$386$32
Acyclovir13$352$27
Montelukast22$305$14
Sulindac12$212$18
Meloxicam12$166$14
Naproxen12$157$13

2015: 13 drugs

Part D drugs prescribed in 2015
Enbrel48$196,554$4,095
Humira19$119,138$6,270
Orencia13$41,262$3,174
Hydroxychloroquine Sulfate111$25,889$233
Uloric14$6,499$464
Methotrexate38$3,942$104
Prednisone94$2,162$23
Celecoxib13$1,926$148
Synthroid13$377$29
Montelukast27$364$13
Sulindac13$180$14
Meloxicam20$139$7
Naproxen13$85$7

2014: 19 drugs

Part D drugs prescribed in 2014
Enbrel53$169,449$3,197
Gilenya13$64,590$4,968
Humira12$55,641$4,637
Cellcept11$16,941$1,540
Celebrex15$9,000$600
Doxycycline Hyclate27$7,356$272
Uloric15$6,869$458
Evoxac12$6,218$518
Methotrexate53$4,786$90
Hydroxychloroquine Sulfate132$3,979$30
Mycophenolate Mofetil16$3,553$222
Voltaren18$2,894$161
Benicar11$1,870$170
Prednisone87$1,585$18
Montelukast20$568$28
Methylprednisolone20$379$19
Meloxicam34$193$6
Sulindac12$113$9
Naproxen12$88$7

2013: 24 drugs

Part D drugs prescribed in 2013
Enbrel49$152,194$3,106
Humira15$58,308$3,887
Xeljanz14$51,545$3,682
Kineret12$29,180$2,432
Cellcept11$24,769$2,252
Celebrex17$7,559$445
Doxycycline Hyclate40$6,983$175
Plaquenil19$5,963$314
Evoxac13$5,859$451
Hydroxychloroquine Sulfate143$3,701$26
Cymbalta14$3,616$258
Methotrexate43$3,217$75
Voltaren18$2,011$112
Benicar12$1,760$147
Prednisone90$1,269$14
Mycophenolate Mofetil14$1,207$86
Doxycycline Monohydrate12$1,060$88
Montelukast22$982$45
Acyclovir15$451$30
Methylprednisolone13$325$25
Meloxicam26$255$10
Naproxen13$179$14
Carbamazepine13$109$8
Sertraline11$59$5

Money from drug and device companies

$7,095 in 2025

Industry payments by year
202512$7,095$7,095
2024213$11,990$13,500
202323$2,150$2,906
202111$2,596$2,596
201933$1,663$1,810

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
E.R. Squibb & Sons L.L.C.Sotyktu$7,095
2 payments
  • Consulting for Sotyktu · 2025-06-09 · $3,655
  • Consulting for Sotyktu · 2025-05-01 · $3,440
See all 2 published payments
Every published payment
E.R. Squibb & Sons L.L.C.Consulting · 2025-06-09Sotyktu$3,655
E.R. Squibb & Sons L.L.C.Consulting · 2025-05-01Sotyktu$3,440
See earlier years (2024, 2023, 2021, 2019)

2024: $13,500

Payments by company in 2024
Boehringer Ingelheim PharmaceuticalsNone$7,910
11 payments
  • Consulting · 2024-12-05 · $6,400
  • Meals · 2024-12-05 · $35
  • Travel · 2024-12-05 · $140
  • Meals · 2024-11-01 · $6
  • Meals · 2024-11-01 · $7
  • Meals · 2024-11-01 · $12
  • Meals · 2024-11-01 · $26
  • Travel · 2024-10-28 · $167
  • Travel · 2024-10-25 · $212
  • Travel · 2024-10-25 · $276
  • Travel · 2024-09-26 · $629
E.R. Squibb & Sons L.L.C.Sotyktu$5,590
2 payments
  • Consulting for Sotyktu · 2024-12-30 · $3,010
  • Consulting for Sotyktu · 2024-07-26 · $2,580

2023: $2,906

Payments by company in 2023
E.R. Squibb & Sons L.L.C.Sotyktu$2,150
1 payment
  • Consulting for Sotyktu · 2023-06-06 · $2,150
Novartis PharmaceuticalsCosentyx$756
2 payments
  • Travel · 2023-09-29 · $708
  • Meals for Cosentyx · 2023-09-20 · $48

2021: $2,596

Payments by company in 2021
Novartis PharmaceuticalsNone$2,596
1 payment
  • Consulting · 2021-09-29 · $2,596

2019: $1,810

Payments by company in 2019
E.R. Squibb & Sons L.L.C.Orencia$1,663
1 payment
  • Consulting for Orencia · 2019-02-22 · $1,663
GlaxoSmithKlineBenlysta$92
1 payment
  • Meals for Benlysta · 2019-04-07 · $92
F. Hoffmann-La Roche AGNon-Covered Product$55
1 payment
  • Meals for Non-Covered Product · 2019-04-04 · $55

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Novartis Pharma AG · Rheumatology Pipeline Studies · 2023This clinician$13,211
E.R. Squibb & Sons, L.L.C. · Study To Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus Or Primary Sjgren'S Syndrome, Or Branebrutinib Treatment Followed By Open-Label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis · 2021This clinician$3,850
E.R. Squibb & Sons, L.L.C. · Study To Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus Or Primary Sjgren'S Syndrome, Or Branebrutinib Treatment Followed By Open-Label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis · 2020This clinician$2,275
E.R. Squibb & Sons, L.L.C. · Study To Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus Or Primary Sjgren'S Syndrome, Or Branebrutinib Treatment Followed By Open-Label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis · 2022This clinician$2,100

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
74.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1669582458
Licence
CA G52227California G52227: Current · expires 2028-03-31
Trained
Johns Hopkins University School of Medicine, 1982 · 44 years ago
Group
Regents of the University of California at Berkeley · University of California San Francisco
Gender
Female
More record details
Sole proprietor
Yes
Taxonomy
Federal specialty code 207RR0500X (207RR0500X)
Mailing address
54 Martha Ave, San Francisco, CA, 94131
NPI first listed
2006-08-30
NPI last updated
2011-04-15

This is when the NPI record was last certified, not a medical board exam.